Ben Zercher
Ben Zercher is a senior research analyst covering biotech and pharma at PitchBook, based in the firm's Seattle office. He conducts research on emerging therapeutics, market dynamics, and investment trends across the life sciences sector. Prior to joining PitchBook, he worked in biotech consulting at Qral Group, focusing on commercial strategy and competitive intelligence. He holds a PhD in chemistry from the University of Washington, where his dissertation focused on characterizing proteins with native mass spectrometry and multidimensional ion mobility.
“LPs are finally seeing returns similar to the sector's pandemic-era heyday, but the bigger question is whether it will last.”
Source→“It's hard to call [the Kelonia deal] an overpay right now. This technology should (in theory) have more durable expression than some other approaches, so there's a premium there. — Ben Zercher, Senior Biotech Analyst, PitchBook”
Source→AI-extracted from podcast / newsletter / paper summaries. May contain errors.